Genomic Alteration in Metastatic Breast Cancer and Its Treatment

Cancers, Free Full-Text

HTRA1 and HTRA2 expression differentially modulate the clinical prognosis of cancer: a multi-omics analysis using bioinformatics approaches

PDF) The Present and Future of Clinical Management in Metastatic Breast Cancer

ESMO Open on X: In this ctDNA analysis of the #FUTURE trial

Copper Chaperone for Superoxide Dismutase Subtypes as a Prognostic Marker in Luminal B Breast Cancer - Yanping Li, Wenfei Du, Rui Yang, Xiaonan Wei, Haibin Li, Xiaoyuan Zhang, 2024

HTRA1 and HTRA2 expression differentially modulate the clinical prognosis of cancer: a multi-omics analysis using bioinformatics approaches

Comparative analysis of protein-protein interaction networks in metastatic breast cancer

JCM, Free Full-Text

Brazilian Journal Of Oncology - Implementing somatic mutation testing in clinical setting: recommendations from a panel of experts

Comparative analysis of protein-protein interaction networks in metastatic breast cancer

PDF) Are There Any Clinically Relevant Subgroups of Triple-Negative Breast Cancer in 2018?

Mapping Cancer Genomic Evolution - NCI

Metastatic Breast Cancer Patients Benefit from Targeted Therapies

PDF] Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

The genomic landscape of metastatic histologic special types of